JP2003524018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003524018A5 JP2003524018A5 JP2001562581A JP2001562581A JP2003524018A5 JP 2003524018 A5 JP2003524018 A5 JP 2003524018A5 JP 2001562581 A JP2001562581 A JP 2001562581A JP 2001562581 A JP2001562581 A JP 2001562581A JP 2003524018 A5 JP2003524018 A5 JP 2003524018A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- conjugate
- domain
- angiogenesis
- affinity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 description 10
- 230000033115 angiogenesis Effects 0.000 description 8
- 102000016359 Fibronectins Human genes 0.000 description 6
- 108010067306 Fibronectins Proteins 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003504 photosensitizing agent Substances 0.000 description 4
- 206010053648 Vascular occlusion Diseases 0.000 description 3
- 208000021331 vascular occlusion disease Diseases 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- MLKYWECXFLBPGE-UHFFFAOYSA-N 3-trimethylstannylbenzoic acid Chemical compound C[Sn](C)(C)C1=CC=CC(C(O)=O)=C1 MLKYWECXFLBPGE-UHFFFAOYSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DDCIMZXBRKWQPW-UHFFFAOYSA-N [Cl+].[Sn+4] Chemical group [Cl+].[Sn+4] DDCIMZXBRKWQPW-UHFFFAOYSA-N 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51208200A | 2000-02-24 | 2000-02-24 | |
| US09/512,082 | 2000-02-24 | ||
| PCT/EP2001/002062 WO2001062800A1 (en) | 2000-02-24 | 2001-02-23 | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003524018A JP2003524018A (ja) | 2003-08-12 |
| JP2003524018A5 true JP2003524018A5 (cg-RX-API-DMAC10.html) | 2008-04-17 |
Family
ID=24037588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001562581A Abandoned JP2003524018A (ja) | 2000-02-24 | 2001-02-23 | フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8097254B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1259548A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2003524018A (cg-RX-API-DMAC10.html) |
| AU (2) | AU4243201A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2400622A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2001062800A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| US8623373B2 (en) * | 2000-02-24 | 2014-01-07 | Philogen S.P.A. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| EP1259548A1 (en) | 2000-02-24 | 2002-11-27 | Eidgenössische Technische Hochschule Zürich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| PL369371A1 (en) | 2002-01-03 | 2005-04-18 | Schering Aktiengesellschaft | New methods for diagnosis and treatment of tumours |
| ES2337566T3 (es) * | 2002-03-11 | 2010-04-27 | Philogen S.P.A. | Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo. |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| EP1514561A1 (en) * | 2003-09-10 | 2005-03-16 | Philogen S.p.A. | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
| DE10348319A1 (de) * | 2003-10-17 | 2005-05-19 | Schering Ag | Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques |
| EP1619501B1 (en) * | 2004-07-22 | 2007-09-26 | Bayer Schering Pharma Aktiengesellschaft | Use of cyanine dyes for the diagnosis of disease associated with angiogenesis |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| SI1817345T1 (sl) * | 2004-11-09 | 2009-10-31 | Philogen Spa | Protitelesa proti tenascinu-C |
| DE502005009389D1 (de) | 2005-11-09 | 2010-05-20 | Morphosys Ag | Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern |
| EP1925664A1 (en) | 2006-11-15 | 2008-05-28 | Scil proteins GmbH | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
| EP2100621A1 (en) | 2008-03-10 | 2009-09-16 | mivenion GmbH | Polyether polyol dendron conjugates with effector molecules for biological targeting |
| US8679488B2 (en) | 2009-08-05 | 2014-03-25 | Philogen S.P.A. | Targeting of bone marrow neovasculature |
| BR112012014417B1 (pt) | 2009-12-14 | 2021-11-09 | Scil Proteins Gmbh | Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina |
| DK2721152T3 (da) | 2011-06-15 | 2019-07-01 | Navigo Proteins Gmbh | Dimere bindingsproteiner baseret på modificerede ubiquitiner |
| WO2012171541A1 (en) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
| EP2861616A1 (en) | 2012-06-13 | 2015-04-22 | Scil Proteins GmbH | Human fusion proteins comprising single chain tnfalpha and targeting domains |
| WO2014094799A1 (en) | 2012-12-19 | 2014-06-26 | Scil-Proteins-Gmbh | Ubiquitin moieties as a means for prolonging serum half-life |
| EP3253785B1 (en) | 2015-02-06 | 2019-04-10 | Navigo Proteins Gmbh | Novel egfr binding proteins |
| DK3322721T3 (da) | 2015-07-16 | 2022-03-14 | Navigo Proteins Gmbh | Nye immunglobulin-bindende proteiner og deres anvendelse i affinitetsoprensning |
| JP2018520675A (ja) | 2015-07-20 | 2018-08-02 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングNavigo Proteins GmbH | ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法 |
| AU2017260274A1 (en) | 2016-05-04 | 2018-11-01 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
| US11230576B2 (en) | 2016-08-11 | 2022-01-25 | Navigo Proteins Gmbh | Alkaline stable immunoglobulin-binding proteins |
| IL310865A (en) | 2016-10-17 | 2024-04-01 | Pfizer | Antibodies against EDB and antibody-drug conjugates |
| EP3689903A4 (en) * | 2017-09-30 | 2022-01-12 | Hefei Lifeon Pharmaceutical Co. Ltd. | BINDING OF PROTEIN TO FIBRONECTIN B DOMAIN |
| WO2019091918A1 (en) | 2017-11-07 | 2019-05-16 | Navigo Proteins Gmbh | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer |
| TWI844524B (zh) | 2018-02-09 | 2024-06-11 | 義大利商費洛根公司 | 靶向edb之il-12組合物 |
| KR20210104106A (ko) | 2018-12-18 | 2021-08-24 | 나피고 프로타인스 게엠베하 | 암 진단 및 치료를 위한 신규 folr1 특이적 결합 단백질 |
| WO2021016091A1 (en) | 2019-07-19 | 2021-01-28 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors |
| WO2021116337A1 (en) * | 2019-12-11 | 2021-06-17 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| ES2987329T3 (es) | 2020-05-22 | 2024-11-14 | Philogen Spa | Terapia con el inmunoconjugado de TNF-a para el tratamiento de tumores cerebrales |
| US20250161475A1 (en) | 2022-03-21 | 2025-05-22 | Philogen S.P.A | Tnfalpha immunoconjugate preparation |
| MX2024011514A (es) | 2022-03-23 | 2024-09-24 | Philogen Spa | Preparacion de un inmunoconjugado de il2. |
| EP4558519A1 (en) | 2022-07-22 | 2025-05-28 | Philogen S.p.A. | Anti-cd28 antibodies |
| WO2024028258A1 (en) | 2022-08-01 | 2024-02-08 | Philochem Ag | Conjugates of psma-binding moieties with cytotoxic agents |
| CN115505040A (zh) * | 2022-08-01 | 2022-12-23 | 江苏艾洛特医药研究院有限公司 | 一种用于检测edb蛋白的免疫组化试剂盒及其应用 |
| CA3266566A1 (en) | 2022-09-06 | 2024-03-14 | Philochem Ag | MULTIVALENT FIBROBLAST ACTIVATING PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS |
| CN118108796B (zh) * | 2024-04-08 | 2024-12-24 | 中国科学院近代物理研究所 | 靶向治疗脑胶质瘤的211At标记多肽及其制备方法 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4341223A (en) * | 1981-02-04 | 1982-07-27 | Lutz Lauralee A | Fluoresceable composition and method of determining fluid flow |
| US4741900A (en) * | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| EP0460709B1 (en) | 1985-01-28 | 1997-05-21 | Xoma Corporation | AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques |
| US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4894326A (en) * | 1986-04-09 | 1990-01-16 | Fred Hutchinson Cancer Research Center | Monoclonal antibody defining oncofetal structure of fibronectin |
| US5243029A (en) * | 1986-04-09 | 1993-09-07 | Fred Hutchinson Cancer Research Center | Oncofetal structure of fibronectin |
| CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
| WO1989006283A1 (en) | 1988-01-11 | 1989-07-13 | Ingene (International Genetic Engineering, Inc.) | Novel plasmid vector with pectate lyase signal sequence |
| EP0330506A3 (en) * | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
| IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
| US5177015A (en) * | 1988-08-12 | 1993-01-05 | Fred Hutchinson Cancer Research Centre | Onco-developmentally regulated α-N-acetylgalactosaminyltransferase |
| US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
| JPH0276598A (ja) | 1988-09-14 | 1990-03-15 | Fujita Gakuen | 抗ed−b抗体 |
| US5270030A (en) * | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| CA2065299C (en) * | 1989-08-09 | 2001-07-24 | Buck A. Rhodes | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5460785A (en) * | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
| US5120830A (en) * | 1990-10-25 | 1992-06-09 | Washington University | Inhibitory peptides against α-2, β-1 mediated mg++ dependent adhesion of platelets to collagen |
| JPH04169195A (ja) | 1990-10-31 | 1992-06-17 | Fujita Gakuen | 抗ed―bモノクローナル抗体 |
| US5140470A (en) * | 1991-01-07 | 1992-08-18 | New Focus, Inc. | Optical mounting apparatus |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5629291A (en) * | 1992-01-31 | 1997-05-13 | La Jolla Cancer Research Foundation | Methods of modulating fibronectin extracellular matrix assembly |
| CA2372813A1 (en) * | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US6749853B1 (en) * | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
| US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
| US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| US5976535A (en) | 1992-06-09 | 1999-11-02 | Neorx Corporation | Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore |
| US5561114A (en) * | 1992-09-25 | 1996-10-01 | Otsuka Pharmaceutical Factory Inc. | Adsorbent for cellular fibronectin, a method for fractional purification of fibronectin and a method of hemocatharisis |
| CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
| US5491130A (en) * | 1992-11-10 | 1996-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Peptide inhibitors of fibronectin and related collagen-binding proteins |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5348485A (en) * | 1993-04-12 | 1994-09-20 | Electronic Retailing Systems Int'l Inc. | Electronic price display system with vertical rail |
| GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US6015897A (en) * | 1993-12-07 | 2000-01-18 | Neorx Corporation | Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota |
| US5523229A (en) * | 1994-03-22 | 1996-06-04 | Trustees Of The University Of Pennsylvania | Antibodies specific for oncofetal fibronectin |
| DE4417865A1 (de) * | 1994-05-20 | 1995-11-23 | Behringwerke Ag | Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie |
| ITFI940095A1 (it) | 1994-05-23 | 1995-11-23 | Molteni & C | Coniugati fotodinamici aventi proprieta' biocide |
| US5648485A (en) | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
| DE4445065A1 (de) * | 1994-12-07 | 1996-06-13 | Diagnostikforschung Inst | Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung |
| CA2165228A1 (en) | 1994-12-27 | 1996-06-28 | Yoshitoshi Itaya | Metal chelate forming peptides and use thereof |
| WO1996023816A1 (en) | 1995-02-01 | 1996-08-08 | British Technology Group Limited | Radiolabelled proteins |
| US5796535A (en) * | 1995-05-12 | 1998-08-18 | Cirrus Logic, Inc. | Sampled amplitude read channel employing a user data frequency synthesizer and a servo data frequency synthesizer |
| WO1997002479A2 (en) | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
| US5808146A (en) * | 1995-11-09 | 1998-09-15 | Emory University | Amino acid analogs for tumor imaging |
| GB9610967D0 (en) * | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| US5913884A (en) * | 1996-09-19 | 1999-06-22 | The General Hospital Corporation | Inhibition of fibrosis by photodynamic therapy |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6394952B1 (en) * | 1998-02-03 | 2002-05-28 | Adeza Biomedical Corporation | Point of care diagnostic systems |
| US6267722B1 (en) * | 1998-02-03 | 2001-07-31 | Adeza Biomedical Corporation | Point of care diagnostic systems |
| CA2326821C (en) | 1998-04-02 | 2010-09-28 | The Board Of Regents Of The University Of Oklahoma | Nucleic acid encoding hyaluronan synthase and methods of use |
| US6296831B1 (en) * | 1998-04-10 | 2001-10-02 | Battelle Memorial Institute | Stimulus sensitive gel with radioisotope and methods of making |
| US5997842A (en) * | 1998-04-13 | 1999-12-07 | Light Sciences Limited Partnership | Radionuclide excited phosphorescent material for administering PDT |
| US20030045681A1 (en) * | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| TWI259837B (en) * | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| US20030176663A1 (en) * | 1998-05-11 | 2003-09-18 | Eidgenossische Technische Hochscule | Specific binding molecules for scintigraphy |
| US6630570B1 (en) * | 1999-04-09 | 2003-10-07 | Insitut für Diagnostikforschung GmbH | Short-chain peptide-dye conjugates as contrast media for optical diagnosis |
| US6171578B1 (en) * | 1999-04-14 | 2001-01-09 | Diatide, Inc. | Benzodiazepine derivatives for imaging thrombi |
| EP1179541B1 (en) * | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| DE19947559A1 (de) | 1999-09-24 | 2001-04-19 | Schering Ag | Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung |
| CA2395567A1 (en) * | 2000-01-12 | 2001-07-19 | Light Sciences Corporation | Novel treatment for eye disease |
| US8623373B2 (en) * | 2000-02-24 | 2014-01-07 | Philogen S.P.A. | Compositions and methods for treatment of angiogenesis in pathological lesions |
| EP1259548A1 (en) | 2000-02-24 | 2002-11-27 | Eidgenössische Technische Hochschule Zürich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| EP1130099A1 (en) | 2000-02-25 | 2001-09-05 | Crucell Holland B.V. | Activated vitronectin as a marker of angiogenesis detected with phage antibodies |
| US6342326B1 (en) * | 2000-05-10 | 2002-01-29 | Beckman Coulter, Inc. | Synthesis and use of acyl fluorides of cyanine dyes |
| WO2001096599A2 (en) | 2000-06-15 | 2001-12-20 | Philogen S.R.L. | Methods for quantitative determination of b-fibronectin in biological fluids and tissues |
| US20020197700A1 (en) | 2000-09-07 | 2002-12-26 | Schering Ag | Receptor of the EDb-fibronectin domains |
| US6693245B2 (en) * | 2000-09-29 | 2004-02-17 | Anritsu Corporation | Electronic balance which is easily assembled, maintained, downsized and improved with respect to weighing performance, and method for manufacturing the same |
| WO2002069907A2 (en) * | 2001-03-07 | 2002-09-12 | Mannkind Corporation | Anti-neovasculature preparations for cancer |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| PL369371A1 (en) | 2002-01-03 | 2005-04-18 | Schering Aktiengesellschaft | New methods for diagnosis and treatment of tumours |
| ES2337566T3 (es) | 2002-03-11 | 2010-04-27 | Philogen S.P.A. | Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo. |
| AR040956A1 (es) * | 2002-07-31 | 2005-04-27 | Schering Ag | Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico |
| JP4169195B2 (ja) | 2003-06-24 | 2008-10-22 | 株式会社河合楽器製作所 | 電子楽音発生装置の記録制御装置 |
| EP1514561A1 (en) * | 2003-09-10 | 2005-03-16 | Philogen S.p.A. | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
| DE10348319A1 (de) * | 2003-10-17 | 2005-05-19 | Schering Ag | Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques |
| US7785591B2 (en) * | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| EP2036576A1 (en) * | 2007-09-17 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | ED-B fibronectin as stratification marker for antitumor drugs |
-
2001
- 2001-02-23 EP EP01915294A patent/EP1259548A1/en not_active Withdrawn
- 2001-02-23 WO PCT/EP2001/002062 patent/WO2001062800A1/en not_active Ceased
- 2001-02-23 AU AU4243201A patent/AU4243201A/xx active Pending
- 2001-02-23 JP JP2001562581A patent/JP2003524018A/ja not_active Abandoned
- 2001-02-23 AU AU2001242432A patent/AU2001242432B2/en not_active Ceased
- 2001-02-23 CA CA002400622A patent/CA2400622A1/en not_active Abandoned
-
2004
- 2004-04-12 US US10/821,930 patent/US8097254B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002514405A5 (cg-RX-API-DMAC10.html) | ||
| JP7722990B2 (ja) | アミロイド沈着物を標的化するための修飾免疫グロブリン | |
| CA2333833A1 (en) | Specific binding molecules for scintigraphy,conjugates containing them and therapeutic method for treatment of angiogenesis | |
| AU2011298369B2 (en) | Peptide or peptide complex binding to 2 integrin and methods and uses involving the same | |
| AU2003243651B2 (en) | Specificity grafting of a murine antibody onto a human framework | |
| CN101981053B (zh) | 聚乙二醇化的AβFAB | |
| ES2440652T3 (es) | Anticuerpos humanizados anti-MAG y sus usos para el tratamiento de apoplejía | |
| JP5221641B2 (ja) | 腫瘍転移の血管新生と関連するフィブロネクチンのed−a抗原 | |
| JP2017503511A5 (cg-RX-API-DMAC10.html) | ||
| US5811522A (en) | Recombinant humanized anti-FB5 antibodies | |
| JP2007228979A (ja) | 癌マーカー用生物合成結合蛋白質 | |
| JP2009149686A (ja) | フィブリンのd二量体断片に特異的なdd−3b6/22から誘導されるヒト化抗体 | |
| JP2009514540A (ja) | 機能−阻止抗−ed−b−フィブロネクチン抗体(private)の同定及び特徴化 | |
| RU2004130428A (ru) | Избирательный направленный перенос в сосудистую сеть опухоли с использованием молекул антител | |
| JP2004135675A (ja) | 哺乳動物ケモカイン | |
| JP2003516934A (ja) | ヒト骨髄前駆細胞阻害性因子−1(mpif−1)を用いる、細胞、組織および器官の損傷を処置または予防する方法 | |
| JP6605331B2 (ja) | 抗体−薬物複合体治療での使用のための免疫造影剤 | |
| KR20230042301A (ko) | 샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트 | |
| JP2026513849A (ja) | Pdgfrアルファを発現するがんを画像診断するための試薬及び方法 | |
| JP2016515093A (ja) | 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤 | |
| EA048681B1 (ru) | Модифицированные иммуноглобулины для нацеливания на амилоидные отложения | |
| BR112018000650B1 (pt) | Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios |